Literature DB >> 21053138

Applications of cell-penetrating peptides as signal transduction modulators for the selective induction of apoptosis.

Sarah Jones1, John Howl.   

Abstract

The discovery of cell-penetrating peptides (CPP) has provided the scientific community with relatively small and increasingly cost-effective molecular agents that readily cross the normally impermeable cell membrane. Thus, as either inert delivery vectors or biologically active agents, CPP can be used to selectively modulate intracellular signal transduction events. Indeed, the survival of many cancer cells is associated with alterations in the function of key intracellular signalling proteins. Accordingly, CPP constructs have been developed to access intracellular target loci in both normal and transformed cells. Thus, CPP are a novel, generic class of signal transduction modulator which can be utilized to specifically induce apoptosis in tumour cells as a potential therapeutic option. However, and particularly at higher concentrations, CPP can induce non-specific membrane perturbations, thus leading to cell death by necrotic mechanisms. This chapter, therefore, focuses on methodologies for the assessment of apoptotic events, including in situ TUNEL analysis, activation of caspase-3, and the MTT assay, whilst also discussing dual Annexin V and propidium iodide staining, an assay used for the quantification of cell populations undergoing apoptosis and/or necrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21053138     DOI: 10.1007/978-1-60761-919-2_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  2 in total

1.  Non-addictive opium alkaloids selectively induce apoptosis in cancer cells compared to normal cells.

Authors:  Monireh Afzali; Padideh Ghaeli; Mahnaz Khanavi; Maliheh Parsa; Hamed Montazeri; Mohammad Hossein Ghahremani; Seyed Nasser Ostad
Journal:  Daru       Date:  2015-02-20       Impact factor: 3.117

2.  Specific targeting of caspase-9/PP2A interaction as potential new anti-cancer therapy.

Authors:  Issam Arrouss; Fariba Nemati; Fernando Roncal; Marie Wislez; Karim Dorgham; David Vallerand; Nathalie Rabbe; Narjesse Karboul; Françoise Carlotti; Jeronimo Bravo; Dominique Mazier; Didier Decaudin; Angelita Rebollo
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.